From hospital spending to cancer prevention, initial public offerings to fish oil pills, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about new trends in the health-care industry, a clinical trial that examined the efficacy of omega3 fatty acids, four everyday items that may contain chemicals linked to cancer, and two stocks that investors need to watch.
Editor's Note: Audio quality is poor in certain places. The Fool regrets this problem.
David Williamson owns shares of Amarin plc (ADR). Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.